| Detected | Trial | Change |
|---|---|---|
| 2026-08-14 | NCT06468033 P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk |
Trial sites expanded: 2 -> 73 locations |
| 2026-08-01 | NCT06290765 Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera |
critical Withdrawn before enrolling |
| 2026-08-01 | NCT06290765 Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera |
critical Trial withdrawn: In alignment with company strategic direction. |
| 2026-08-01 | NCT06290765 Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera |
Enrollment reduced: 70 -> 0 participants |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05481151 | A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV | Polycythemia Vera | Active, Not Recruiting |
| NCT04285086 | Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With… | Essential Thrombocythemia | Active, Not Recruiting |
| NCT06468033 | P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | Primary Myelofibrosis | Active, Not Recruiting |
| Phase 2 | |||
| NCT05485948 | A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant… | Polycythemia Vera | Active, Not Recruiting |
| NCT05482971 | A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101… | Essential Thrombocythemia | Active, Not Recruiting |
| Phase 1 | |||
| NCT07053904 | Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors | Advanced Solid Tumors | Enrolling by Invitation |